A Phase IIb expansion trial of savolitinib in combination with Tagrisso® in Non Small Cell Lung Cancer patients.
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Osimertinib (Primary) ; Savolitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Sep 2016 New trial record
- 02 Aug 2016 According to a Chi-Med media release, company expects to complete this Phase IIb expansion study by the end of 2016.